WO2003074677A3 - MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE - Google Patents

MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE Download PDF

Info

Publication number
WO2003074677A3
WO2003074677A3 PCT/US2003/006497 US0306497W WO03074677A3 WO 2003074677 A3 WO2003074677 A3 WO 2003074677A3 US 0306497 W US0306497 W US 0306497W WO 03074677 A3 WO03074677 A3 WO 03074677A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
chk
mchks
modifiers
pathway
Prior art date
Application number
PCT/US2003/006497
Other languages
French (fr)
Other versions
WO2003074677A2 (en
Inventor
Helen Francis-Lang
Monique Nicoll
Timothy S Heuer
Original Assignee
Exelixis Inc
Helen Francis-Lang
Monique Nicoll
Timothy S Heuer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Helen Francis-Lang, Monique Nicoll, Timothy S Heuer filed Critical Exelixis Inc
Priority to AU2003213693A priority Critical patent/AU2003213693A1/en
Publication of WO2003074677A2 publication Critical patent/WO2003074677A2/en
Publication of WO2003074677A3 publication Critical patent/WO2003074677A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human MCHK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of MCHK are provided.
PCT/US2003/006497 2002-03-01 2003-02-28 MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE WO2003074677A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213693A AU2003213693A1 (en) 2002-03-01 2003-02-28 MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36122302P 2002-03-01 2002-03-01
US36122602P 2002-03-01 2002-03-01
US36124002P 2002-03-01 2002-03-01
US60/361,240 2002-03-01
US60/361,223 2002-03-01
US60/361,226 2002-03-01

Publications (2)

Publication Number Publication Date
WO2003074677A2 WO2003074677A2 (en) 2003-09-12
WO2003074677A3 true WO2003074677A3 (en) 2004-03-25

Family

ID=27792175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006497 WO2003074677A2 (en) 2002-03-01 2003-02-28 MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2003213693A1 (en)
WO (1) WO2003074677A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070303A2 (en) * 2006-10-19 2008-06-12 The University Of Chicago Therapeutics to inhibit mll-menin interaction for treating leukemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLIN. CANCER RES., vol. 7, no. SUPPL., 2001, pages 3792S *
DATABASE DRUGU [online] KOHN ET AL.: "Comparison of UCN-01 and a novel cellcycle checkpoint inhibitor: similarities and differences in their mechanism of action", XP002970313, accession no. STN Database accession no. 2002-11413 *

Also Published As

Publication number Publication date
WO2003074677A2 (en) 2003-09-12
AU2003213693A1 (en) 2003-09-16
AU2003213693A8 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2003074674A3 (en) MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099053A3 (en) Slc22as as modifiers of the p53 pathway and methods of use
WO2002098356A3 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1438432A4 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004005486A3 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2004005484A3 (en) Snrks as modifiers of chk and branching morphogenesis and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004024883A3 (en) PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005052134A3 (en) Ttbks as modifiers of the beta catenin pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP